Sophiris Bio Inc. (NASDAQ: SPHS) is a biopharmaceutical company developing a clinical-stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH or enlarged prostate), which it believes is an unsatisfied patient population with significant market potential. Sophiris is currently developing PRX302 for the treatment of BPH symptoms which is designed to be as efficacious as pharmaceuticals, less invasive than the surgical interventions, and without the sexual side effects seen with existing treatments. PRX302 is currently in Phase 3 clinical development with a blinded interim analysis expected in the second half of 2014 followed by a complete data analysis in the second half of 2015. For more information, please visit www.sophiris.com.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
N/A
Frequently Asked Questions
What is market cap of Sophiris Bio Inc?
The market cap of Sophiris Bio Inc is $0.00
What is the 52 week high for Sophiris Bio Inc?
The 52 week high for Sophiris Bio Inc is $0.0342.
What is the 52 week low for Sophiris Bio Inc?
The 52 week low for Sophiris Bio Inc is $0.00.
What is the 50-day moving average of Sophiris Bio Inc?
The 50-day moving average of Sophiris Bio Inc is 0.0001.